Risks Testing plan The brief's ten assumptions What would change this Plan

The brief's ten assumptions, tested

The brief lists ten assumptions and marks each as requiring validation; this is the ruling on each.

The ten assumptions, ruled on

Assumption: Market growth sufficient to support $350M by Year 3
Verdict: Fails. The markets grow at 4.7% to 14.9% and are large enough; the reachable pool at 2029 is $732.5M. What fails is the share and the calendar, not the growth

Assumption: Substrate criticality: ultra-thin fine-pattern substrates are critical and unsubstitutable in at least one segment
Verdict: Holds in part. They are critical in Abbott's and Medtronic's CGM architecture, in thin-film neural electrodes and in mapping catheters. They are substituted by wire in Dexcom's, which is the second largest participant by revenue after Abbott and the one this technology cannot serve at all

Assumption: OEMs will continue to source a meaningful portion externally
Verdict: Fails for CGM, holds for neurostimulation leads and for pharmaceutical drug-delivery devices. The distinction is whether the part is what the buyer competes on

Assumption: Higher-value tiers are commercially accessible to qualified new entrants and allow materially higher margins
Verdict: Holds on accessibility, fails on margin. The tiers are open; the merchant tier's operating margin tops out near 12% at the industry's largest operator

Assumption: Margin ranges of 10-15%, up to 40%, and 30-60% are achievable
Verdict: Holds as gross margin, fails as operating margin. See the unit economics section

Assumption: ISO 13485 recertification and expanded ISO 10993 within the horizon
Verdict: Holds on cost, and it is the calendar rather than the cost that binds

Assumption: Certified lines can serve medical without materially impairing efficiency
Verdict: Holds with a cost. Change control rather than cleanliness is the binding constraint, and the price is reduced effective utilization

Assumption: Partnership or acquisition meaningfully reduces time-to-market or execution risk
Verdict: Holds. An acquisition with a live certificate removes about a year, which is the single largest available improvement to the plan

Assumption: Unit economics and adoption consistent with all four targets
Verdict: Fails. No combination of the modeled inputs reaches them

Assumption: Competitive intensity will not compress margins below what the targets require before minimum viable scale
Verdict: Not applicable as framed, because the margins do not reach the targets even before competitive compression. The risk that does apply is price erosion in private-label work, which is treated in the risk register

The brief lists ten assumptions and marks each as requiring validation. This is the ruling on each.

Assumptions 2, 3 and 5 are the ones the case turns on, and each of them holds only in part. That pattern, rather than any single failure, is what produces the verdict.

Section added · Added during the review cycle. The brief lists ten assumptions and marks each as requiring validation, and an assumption tested only implicitly inside another section cannot be checked off by the reader who asked for it. Declared here rather than left as an undeclared heading in the memo.